Our data demonstrated that, a group of human breast tumors that can be identified by screening for Shh ligand expression might be amenable to treatment with Hh signaling pathway inhibitors, such as cyclopamine and GDC-0449. This evidence concerns the gene SHH and breast neoplasm.